Alpha 2.0
Login Register
» Articles » PMID: 32597466

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Overview
Journal Clin Infect Dis
Publisher Oxford University Press
Specialty Infectious Diseases
Date 2020 Jun 30
PMID 32597466
Citations 73
Authors
Boghuma K Titanji
Monica M Farley
Ashish Mehta
Randi Connor-Schuler
Abeer Moanna
Sushma K Cribbs
Jesse OShea
Kathryn DeSilva
Bonnie Chan
Alex Edwards
Christina Gavegnano
Raymond F Schinazi
Vincent C Marconi
Affiliations
Soon will be listed here.
Abstract

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

Citing Articles

Severe COVID-19 infection: An institutional review and literature overview.

Akpoviroro O, Sauers N, Uwandu Q, Castagne M, Akpoviroro O, Humayun S PLoS One. 2024; 19(8):e0304960.

PMID: 39163410 PMC: 11335168. DOI: 10.1371/journal.pone.0304960.

Metagenomic next-generation sequencing of nasopharyngeal microbiota in COVID-19 patients with different disease severities.

Aljabr W, Dandachi I, Abbas B, Karkashan A, Al-Amari A, AlShahrani D Microbiol Spectr. 2024; 12(5):e0416623.

PMID: 38557102 PMC: 11237758. DOI: 10.1128/spectrum.04166-23.

Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection.

Chanda D, Del Rivero T, Ghimire R, More S, Mitrani M, Bellio M Viruses. 2024; 16(2).

PMID: 38400048 PMC: 10892347. DOI: 10.3390/v16020273.

Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis.

Song W, Sun S, Feng Y, Liu L, Gao T, Xian S Medicine (Baltimore). 2023; 102(48):e36313.

PMID: 38050265 PMC: 10695502. DOI: 10.1097/MD.0000000000036313.

Kinetics of C-reactive protein during extracorporeal membrane oxygenation.

Lichter Y, Gal Oz A, Carmi U, Adi N, Nini A, Angel Y Int J Artif Organs. 2023; 47(1):41-48.

PMID: 38031425 PMC: 10787388. DOI: 10.1177/03913988231213511.

References
1.
Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View
2.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View
3.
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A . Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395(10223):e30-e31. PMC: 7137985. DOI: 10.1016/S0140-6736(20)30304-4. View
4.
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D . COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020; 20(4):400-402. PMC: 7158903. DOI: 10.1016/S1473-3099(20)30132-8. View
5.
Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D . Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020; 81(2):318-356. PMC: 7177073. DOI: 10.1016/j.jinf.2020.04.017. View